

EIP



IPKat: Further analysis of Generics (t/a Mylan) v Yeda and Teva

In addition to an [earlier summary](#) by Darren Smyth of the ruling in Generics (t/a Mylan) v Yeda and Teva, Darren has provided further analysis for the [IPKat](#).

Darren's article looks at the issue of the interpretation and clarity of two features in the patent claims.

The case relates to a European patent owned by Yeda (for which Teva is exclusive licensee) for Teva's glatiramer acetate product marketed under the trademark Copaxone.